What is HC Wainwright’s Forecast for FDMT FY2026 Earnings?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Investment analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Wednesday, November 12th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($4.20) for the year, up from their previous estimate of ($4.22). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ FY2027 earnings at ($4.75) EPS and FY2028 earnings at ($4.87) EPS.

Other analysts have also issued reports about the company. Barclays dropped their price target on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday. Roth Capital dropped their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Leerink Partners reissued an “outperform” rating and set a $17.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Finally, Morgan Stanley raised shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $28.70.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT traded up $0.86 during mid-day trading on Friday, reaching $11.14. 254,089 shares of the company’s stock traded hands, compared to its average volume of 857,217. The business has a 50-day simple moving average of $9.25 and a 200 day simple moving average of $6.21. The stock has a market cap of $636.43 million, a P/E ratio of -2.95 and a beta of 2.96. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.01. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FDMT. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth $39,000. Y Intercept Hong Kong Ltd purchased a new position in 4D Molecular Therapeutics during the first quarter valued at $41,000. Los Angeles Capital Management LLC bought a new stake in 4D Molecular Therapeutics during the second quarter valued at about $42,000. Quadrature Capital Ltd purchased a new stake in 4D Molecular Therapeutics in the second quarter worth about $42,000. Finally, Farther Finance Advisors LLC raised its stake in shares of 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after buying an additional 2,674 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the completion of the sale, the insider directly owned 3,594 shares in the company, valued at $43,128. The trade was a 42.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders sold 9,128 shares of company stock valued at $92,100. 9.60% of the stock is currently owned by company insiders.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.